GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis
GCF
Smoking Effects on GCF GCF IL-17A AND IL-17 Levels and Oxidative Status of Patients Receiving Periodontal Treatment
1 other identifier
observational
30
1 country
1
Brief Summary
This study was performed to evaluate the effects of both periodontal treatment and smoking on the gingival crevicular fluid(GCF) levels of interleukin (IL)-17A, IL-17E, Total oxidative stress(TOS) and total antioxidant capasity(TAOC) in smoking and non-smoking patients with severe chronic periodontitis. Systemically healthy 15 smoker,15 non-smoker with chronic periodontitis were attended for the study. Periodontal status were determined by recording periodontal clinical measurements. GCF samples were collected at the baseline, at the end of initial periodontal treatment and 4 weeks after periodontal flap surgery. The data were tested statistically by the Student t and paired sample t tests.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 10, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 10, 2019
CompletedFirst Submitted
Initial submission to the registry
October 2, 2019
CompletedFirst Posted
Study publicly available on registry
October 3, 2019
CompletedOctober 4, 2019
October 1, 2019
1.7 years
October 2, 2019
October 3, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
GCF IL-17A VOLUME
IL-17A is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.
GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
GCF IL-17E VOLUME
IL-17E is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.
GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
GCF TOTAL OXIDATIVE STRESS (TOS) LEVEL
TOS is the measurement of oxidative stress amount and given as mmol/L unit. Its amount changes due to inflammation caused by periodontal disease.
GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
GCF TOTAL ANTIOXIDANT CAPASITY (TAOC)
TAOC is the antioxidant amount measured and given as μmol H2O2 Eq/L unit. Its amount changes due to inflammation caused by periodontal disease.
GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
Study Arms (2)
smokers + periodontitis
Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.
nonsmoker + periodontitis
Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.
Eligibility Criteria
Patients with chronic periodontitis (with an age range of 35 to 60 years) seeking dental treatment at the Periodontology Clinic, School of Dentistry, Ondokuz Mayis University, were included in the present study.
You may qualify if:
- individuals aged ˃35 years and having ≥16 teeth diagnosed as chronic periodontitis
- not received any periodontal therapy within the previous 6 months;
- not received antibiotic/anti-inflammatory drug treatment within the previous 6 months.
You may not qualify if:
- receiving medical treatment for cancer, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, or any other systemic disease;
- being pregnant or being in the period of menopause or lactation;
- receiving any drug therapy that might affect the clinical characteristics of periodontitis;
- usage of systemic antimicrobials during the 6 weeks prior to data collection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Müge Lütfioğlu
Samsun, Atakum, 55039, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
MÜGE LÜTFİOĞLU
assoc. prof.
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
October 2, 2019
First Posted
October 3, 2019
Study Start
October 10, 2017
Primary Completion
July 10, 2019
Study Completion
July 10, 2019
Last Updated
October 4, 2019
Record last verified: 2019-10